PDZD3 Antibody

What is PDZD3 and what cellular functions is it involved in?

PDZD3, also known as PDZ Domain Containing 3 (alternative names: IKEPP, NHERF4, PDZK2), is a protein with a calculated molecular weight of approximately 61 kDa, although it typically appears between 54-60 kDa in experimental conditions . The protein contains PDZ domains that mediate protein-protein interactions, particularly in epithelial cells. PDZD3 is involved in the organization of membrane protein complexes, regulation of ion transporters, and maintenance of epithelial cell polarity. It functions as a scaffold protein that can interact with multiple binding partners through its PDZ domains, facilitating the assembly of functional protein complexes at cellular membranes. The gene ID is 79849 according to NCBI database references .

What are the key differences between monoclonal and polyclonal PDZD3 antibodies?

Monoclonal PDZD3 antibodies, such as the mouse monoclonal 1F2 clone, recognize a single epitope on the PDZD3 protein, providing high specificity for that particular epitope . This makes them valuable for applications requiring consistent lot-to-lot reproducibility and detection of specific protein isoforms or regions. Polyclonal PDZD3 antibodies, typically raised in rabbits, recognize multiple epitopes on the PDZD3 protein . This multi-epitope recognition can enhance detection sensitivity, especially in applications where the protein might be partially denatured or when the target epitope may be masked. Polyclonal antibodies are generally more robust across various applications, as evidenced by their validation in multiple techniques including Western blot, immunoprecipitation, ELISA, and immunohistochemistry . When selecting between monoclonal and polyclonal PDZD3 antibodies, researchers should consider the specific experimental requirements, including detection sensitivity, specificity needs, and the nature of the sample preparation.

What experimental applications are PDZD3 antibodies validated for?

PDZD3 antibodies have been validated for multiple experimental applications, with varying degrees of optimization for each technique:

Different antibodies show various reactivity patterns, with some specifically validated for human samples, while others demonstrate cross-reactivity with mouse and rat PDZD3 . When designing experiments, it is critical to select antibodies that have been validated for both your application of interest and the species being studied. For optimal results, always perform validation experiments in your specific experimental system before proceeding with larger studies.

What is the expected molecular weight of PDZD3 in Western blot applications?

While the calculated molecular weight of PDZD3 based on its amino acid sequence (571 amino acids) is 61 kDa, the observed molecular weight in Western blot applications typically ranges between 54-60 kDa . This discrepancy between calculated and observed molecular weights is common in protein analysis and may be attributed to several factors including: post-translational modifications that alter protein migration, protein folding effects that persist even under denaturing conditions, or splice variants of the protein that may be expressed in different tissues. When performing Western blot analysis of PDZD3, researchers should anticipate detecting bands within this 54-60 kDa range rather than precisely at the calculated molecular weight. Multiple bands within this range may indicate the presence of different isoforms or post-translationally modified versions of the protein.

How should I optimize Western blot protocols for PDZD3 detection?

Optimization of Western blot protocols for PDZD3 detection requires attention to several key parameters:

• Antibody dilution: Start with the manufacturer's recommended dilution range of 1:500-1:1000 for PDZD3 antibodies . Perform a dilution series to determine the optimal concentration for your specific antibody lot and sample type.

• Sample preparation: For tissue samples, PDZD3 has been successfully detected in rat kidney, mouse colon, and mouse kidney tissues . Ensure complete lysis using buffers containing appropriate detergents (typically RIPA buffer with protease inhibitors).

• Protein loading: Load 20-50 μg of total protein per lane initially, adjusting based on expression levels in your tissue of interest.

• Transfer conditions: Due to PDZD3's molecular weight (54-60 kDa), standard transfer conditions (100V for 60-90 minutes) using PVDF membranes typically yield good results.

• Blocking conditions: Use 5% non-fat dry milk or BSA in TBST for blocking, testing both to determine which provides better signal-to-noise ratio.

• Antibody incubation: Incubate primary antibody overnight at 4°C with gentle agitation to maximize specific binding while minimizing background.

• Detection system: HRP-conjugated secondary antibodies with enhanced chemiluminescence detection provide good sensitivity for PDZD3, but fluorescent secondary antibodies may offer advantages for quantitative analysis.

Positive controls using samples known to express PDZD3 (such as kidney or colon tissue) are essential for protocol validation . Always include negative controls and consider including samples where PDZD3 has been knocked down to confirm antibody specificity.

What are the considerations for using PDZD3 antibody pairs in ELISA development?

When developing an ELISA for PDZD3 detection using antibody pairs, several critical factors must be addressed:

• Pair selection: Utilize validated antibody pairs, such as the rabbit polyclonal capture antibody and mouse polyclonal detection antibody combination available commercially . These pairs are specifically designed to recognize different epitopes on PDZD3 without competitive binding.

• Assay format: A sandwich ELISA format is typically most effective, with the capture antibody immobilized on the plate surface and the detection antibody labeled or used with a labeled secondary antibody.

• Cross-reactivity assessment: Even when using commercially validated pairs, verify the absence of cross-reactivity with similar PDZ domain-containing proteins to ensure specificity for PDZD3.

• Standard curve development: Recombinant PDZD3 protein should be used to establish a standard curve, covering a concentration range appropriate for your expected sample concentrations (typically 0.1-1000 ng/mL).

• Sample dilution optimization: Perform serial dilutions of your samples to ensure they fall within the linear range of the standard curve and to identify potential matrix effects.

• Blocking optimization: Test different blocking agents (BSA, casein, non-fat dry milk) to minimize background while maintaining specific signal.

• Antibody concentrations: Titrate both capture and detection antibodies to determine optimal concentrations that maximize specific signal while minimizing background noise.

• Validation: Confirm ELISA results using alternative methods such as Western blot to validate the quantitative accuracy of your assay.

The commercially available PDZD3 antibody pairs are specifically designed for human PDZD3 detection , so researchers working with animal models should verify cross-reactivity or seek species-specific alternatives.

How can I optimize immunoprecipitation protocols when using PDZD3 antibodies?

Optimizing immunoprecipitation (IP) protocols for PDZD3 requires attention to several critical parameters:

• Antibody selection: Choose PDZD3 antibodies specifically validated for IP applications, such as the rabbit polyclonal antibodies that have demonstrated successful results with mouse kidney tissue .

• Antibody amount: Start with the recommended range of 0.5-4.0 μg of antibody per 1.0-3.0 mg of total protein lysate . Titrate the antibody amount to find the optimal ratio for your specific experimental conditions.

• Lysis buffer selection: Use a lysis buffer that preserves protein-protein interactions if co-IP is the goal (e.g., NP-40 or Triton X-100 based buffers with physiological salt concentrations). For straight IP of PDZD3, a more stringent RIPA buffer may reduce non-specific binding.

• Pre-clearing: Pre-clear lysates with protein A/G beads to reduce non-specific binding, especially when working with complex tissue samples like kidney tissue.

• Antibody-bead conjugation: For cleaner results, consider pre-conjugating the PDZD3 antibody to protein A/G beads before adding to the lysate, rather than adding antibody directly to the lysate.

• Incubation conditions: Optimize antibody-lysate incubation time (typically 2-4 hours at 4°C) and bead incubation time (typically 1 hour at 4°C) to maximize specific capture while minimizing non-specific binding.

• Wash stringency: Develop a washing protocol that removes non-specifically bound proteins while retaining PDZD3 and its legitimate binding partners. This typically involves multiple washes with decreasing salt concentrations.

• Elution conditions: For Western blot analysis post-IP, direct elution in SDS sample buffer at 95°C for 5 minutes is usually effective. For mass spectrometry or maintenance of protein-protein interactions, milder elution conditions may be preferable.

When analyzing IP results, always include controls such as IgG control (same species as your PDZD3 antibody) and input sample (typically 5-10% of the lysate used for IP) .

Why might I observe multiple bands when using PDZD3 antibodies in Western blot?

The observation of multiple bands when using PDZD3 antibodies in Western blot can be attributed to several biological and technical factors:

• Protein isoforms: PDZD3 may exist in multiple splice variants, resulting in proteins of different molecular weights. While the reference protein is 571 amino acids with a calculated molecular weight of 61 kDa, shorter isoforms may be expressed in specific tissues .

• Post-translational modifications (PTMs): PDZD3 may undergo various PTMs such as phosphorylation, glycosylation, or ubiquitination, which can alter its electrophoretic mobility. These modifications can result in bands appearing at higher molecular weights than expected.

• Protein degradation: Partial proteolysis during sample preparation can generate PDZD3 fragments that appear as lower molecular weight bands. Ensure your lysis buffer contains appropriate protease inhibitors and samples are kept cold during processing.

• Cross-reactivity: Antibodies, particularly polyclonal antibodies, may recognize proteins with similar epitopes to PDZD3. Compare the pattern of bands observed with the expected molecular weight range of 54-60 kDa .

• Non-specific binding: Insufficient blocking or high antibody concentrations can lead to non-specific binding. Optimize blocking conditions and antibody dilutions (1:500-1:1000 is recommended for most PDZD3 antibodies) .

To determine which bands represent genuine PDZD3 detection:

• Compare observed bands to the expected 54-60 kDa range

• Perform validation with positive control tissues known to express PDZD3 (e.g., kidney and colon tissues)

• Consider using different PDZD3 antibodies targeting distinct epitopes to confirm specific bands

• Implement knock-down or knock-out controls if available to identify bands that disappear with reduced PDZD3 expression

How do I interpret discrepancies in PDZD3 detection between different antibody clones?

Discrepancies in PDZD3 detection between different antibody clones are common and can be systematically analyzed to extract valuable biological information:

• Epitope differences: Different antibodies target distinct epitopes on PDZD3. Monoclonal antibodies (like clone 1F2) recognize a single epitope, while polyclonal antibodies recognize multiple epitopes . These epitope differences may result in differential detection of:

  • Specific protein conformations

  • Protein isoforms with or without certain domains

  • Proteins with post-translational modifications that mask specific epitopes

• Cross-reactivity profiles: Each antibody has a unique cross-reactivity profile with other proteins. Compare the datasheet validation data for each antibody to assess potential cross-reactivity with related PDZ domain-containing proteins.

• Sensitivity differences: Antibodies vary in their binding affinities to PDZD3, resulting in different detection sensitivities. Polyclonal antibodies often provide higher sensitivity due to multiple epitope recognition.

• Application-specific performance: Some antibodies perform better in certain applications than others. For instance, an antibody validated for both WB and IHC may show different relative performance in these applications compared to another antibody .

When faced with discrepancies:

• Map the epitopes recognized by each antibody if this information is available

• Test multiple antibodies in parallel on the same samples

• Consider the observed band pattern in relation to expected molecular weight (54-60 kDa)

• Validate findings with complementary techniques (e.g., mass spectrometry)

• Use genetic approaches (knockdown/knockout) to confirm specificity

These discrepancies, when properly analyzed, can provide insights into protein isoforms, post-translational modifications, or protein-protein interactions affecting epitope accessibility.

What controls are essential when using PDZD3 antibodies in research?

Implementing appropriate controls is critical when using PDZD3 antibodies to ensure result validity and interpretability:

For quantitative analyses, include a standard curve generated with recombinant PDZD3 protein when possible. When performing co-immunoprecipitation with PDZD3 antibodies, always include an IgG control from the same species as the PDZD3 antibody to identify non-specific protein binding to the antibody or beads .

How can PDZD3 antibodies be utilized in protein-protein interaction studies?

PDZD3 antibodies offer powerful tools for investigating protein-protein interactions due to PDZD3's role as a scaffold protein with multiple PDZ domains. Several methodological approaches can be implemented:

• Co-immunoprecipitation (Co-IP):

  • Use PDZD3 antibodies validated for IP applications (such as rabbit polyclonal antibodies) with 0.5-4.0 μg antibody per 1.0-3.0 mg protein lysate

  • Select lysis buffers that preserve protein-protein interactions (typically containing 0.5-1% NP-40 or Triton X-100 with physiological salt concentrations)

  • Analyze precipitates for both PDZD3 and potential interaction partners

  • Include appropriate controls (IgG control, input sample) to distinguish specific from non-specific interactions

• Proximity Ligation Assay (PLA):

  • Combine PDZD3 antibodies with antibodies against suspected interaction partners

  • Requires antibodies from different host species for standard PLA protocols

  • Provides spatial information about protein interactions in situ

  • Enables quantification of interaction events at single-molecule resolution

• Pull-down assays with recombinant domains:

  • Use PDZD3 antibodies to validate interactions identified in pull-down experiments with recombinant PDZ domains

  • Confirm that interactions observed with isolated domains occur with the full-length PDZD3 protein in cellular contexts

• Immunofluorescence co-localization:

  • Combine PDZD3 antibodies with antibodies against potential interaction partners in multicolor immunofluorescence

  • Analyze co-localization patterns, particularly at membrane compartments

  • Apply quantitative co-localization analysis (Pearson's correlation, Manders' coefficients)

• Crosslinking immunoprecipitation (CLIP):

  • Use chemical crosslinkers to stabilize transient protein-protein interactions

  • Perform IP with PDZD3 antibodies under more stringent washing conditions

  • Identify interaction partners by mass spectrometry

When designing these experiments, consider that PDZ domain interactions typically involve the extreme C-terminus of the binding partner. Therefore, antibodies targeting the C-terminal region of PDZD3 might interfere with certain protein-protein interactions. To comprehensively map the PDZD3 interactome, combining multiple approaches and using antibodies targeting different epitopes is recommended.

What approaches can improve specificity in multiplex detection systems using PDZD3 antibodies?

Achieving high specificity in multiplex detection systems that include PDZD3 antibodies requires careful optimization of several parameters:

• Antibody selection and validation:

  • Choose antibodies raised in different host species for simultaneous detection (e.g., rabbit polyclonal for PDZD3 and mouse antibodies for other targets)

  • Validate each antibody individually before combining in multiplex assays

  • Use antibody pairs specifically designed for complementary detection, such as the matched antibody pairs available for PDZD3

• Cross-reactivity elimination:

  • Perform extensive cross-reactivity testing between all antibodies and detection systems in your multiplex panel

  • Pre-absorb antibodies against potentially cross-reactive proteins

  • Use highly cross-adsorbed secondary antibodies to minimize species cross-reactivity

• Signal separation strategies:

  • Implement spectral unmixing algorithms when using fluorophores with overlapping emission spectra

  • Consider sequential detection protocols for targets that may interact or co-localize

  • Utilize antibody-specific detection systems (e.g., directly conjugated primaries with distinct fluorophores)

• Computational approaches:

  • Apply computational design strategies similar to those used in bispecific antibody development to predict and minimize negative interactions

  • Utilize machine learning algorithms for automated signal separation and quantification

  • Implement iterative design strategies that cycle between sequence design and protein modeling

• Control systems:

  • Include single-stained controls for each antibody in the multiplex panel

  • Use biological samples with known expression patterns of PDZD3 and other targets

  • Implement fluorescence minus one (FMO) controls to set accurate detection thresholds

For multiplex systems including PDZD3 detection in tissues or cells, preliminary experiments should establish the optimal fixation and antigen retrieval conditions that maintain epitope integrity for all targets in the panel. When developing multiplex ELISAs, careful optimization of capture and detection antibody concentrations is essential to balance sensitivity and specificity for each target.

How can computational approaches enhance PDZD3 antibody specificity and performance?

Computational approaches offer powerful tools to enhance PDZD3 antibody specificity and performance, drawing inspiration from methods used in bispecific antibody development :

• Epitope mapping and optimization:

  • Computational prediction of immunogenic epitopes on PDZD3 that are distinct from related PDZ domain-containing proteins

  • In silico analysis of epitope conservation across species for antibodies intended for cross-species applications

  • Structure-based design of synthetic peptide immunogens that maximize specificity

• Negative state modeling:

  • Implement negative state modeling, which predicts unwanted binding interactions (similar to the approach described for bispecific antibody design)

  • Create an ensemble of alternative negative state conformations to improve specificity prediction

  • Use iterative strategies that cycle between sequence design and protein docking to refine models

• Antibody-antigen interaction simulation:

  • Molecular dynamics simulations to predict binding kinetics and stability

  • Calculation of binding energy landscapes to identify optimal binding configurations

  • Prediction of post-translational modification effects on antibody-epitope interactions

• Machine learning applications:

  • Develop algorithms that predict cross-reactivity based on epitope sequence and structural similarity to other proteins

  • Train neural networks on antibody performance data to optimize antibody selection for specific applications

  • Implement deep learning approaches for image analysis in immunohistochemistry or immunofluorescence applications

• Structure-guided antibody engineering:

  • In silico maturation of antibody sequences to enhance affinity while maintaining specificity

  • Computational design of mutations that improve stability without affecting antigen recognition

  • Virtual screening of antibody variants to predict performance before experimental validation

These computational approaches can be particularly valuable when designing new PDZD3 antibodies or when selecting optimal antibodies from existing libraries for specific research applications. The integration of experimental validation data with computational predictions in an iterative process, similar to the multi-round design strategy described for bispecific antibodies , can lead to significant improvements in antibody specificity and performance.

How can PDZD3 antibodies contribute to studies of membrane protein complexes?

PDZD3 antibodies provide valuable tools for investigating membrane protein complexes, given PDZD3's role as a scaffold protein involved in organizing membrane-associated protein assemblies:

• Membrane microdomain isolation and analysis:

  • Use PDZD3 antibodies in immunoprecipitation to isolate intact membrane microdomains containing PDZD3 and associated proteins

  • Combine with detergent-resistant membrane fraction isolation to study lipid raft-associated complexes

  • Apply proteomic analysis to identify the complete composition of PDZD3-containing membrane complexes

• Super-resolution microscopy applications:

  • Utilize PDZD3 antibodies conjugated to photoswitchable fluorophores for STORM/PALM imaging

  • Investigate nanoscale organization of PDZD3-containing complexes at the plasma membrane

  • Combine with antibodies against known or suspected interaction partners for multi-color super-resolution imaging of protein complex architecture

• Functional analysis of transporters and channels:

  • Study the role of PDZD3 in regulating ion transporter and channel activity

  • Combine PDZD3 immunostaining with functional assays of membrane protein activity

  • Investigate how PDZD3 scaffolding affects the spatial organization and function of transport complexes

• Dynamics of complex assembly and disassembly:

  • Use PDZD3 antibodies in live-cell imaging approaches to track complex formation

  • Investigate how stimuli affect the composition and localization of PDZD3-containing complexes

  • Apply FRAP (Fluorescence Recovery After Photobleaching) with fluorescently-labeled PDZD3 antibodies to study turnover rates of complex components

• Epithelial polarity studies:

  • Examine PDZD3 localization in relation to apical and basolateral membrane domains

  • Investigate how PDZD3 contributes to the establishment and maintenance of epithelial cell polarity

  • Study how disruption of PDZD3 scaffolding affects polarized protein distribution

These applications require carefully validated PDZD3 antibodies with confirmed specificity in the relevant experimental systems. For immunofluorescence and super-resolution microscopy applications, antibodies must be carefully selected to ensure they recognize the native conformation of PDZD3 in fixed cells and tissues. When studying dynamic processes, consideration should be given to whether antibody binding might perturb the natural behavior of PDZD3-containing complexes.

What quantitative approaches are recommended for analyzing PDZD3 expression data?

Quantitative analysis of PDZD3 expression requires rigorous methodological approaches to ensure accuracy and reproducibility:

• Western blot quantification:

  • Use digital image capture systems rather than film for linear dynamic range

  • Perform densitometric analysis using software that can distinguish closely spaced bands

  • Always normalize PDZD3 signals to appropriate loading controls

  • Include standard curves with recombinant PDZD3 protein when absolute quantification is required

  • Account for the observed molecular weight range (54-60 kDa) when selecting regions for quantification

• ELISA-based quantification:

  • Utilize matched antibody pairs specifically designed for PDZD3 quantification

  • Generate standard curves using recombinant PDZD3 protein

  • Ensure samples fall within the linear range of the standard curve

  • Perform technical replicates (minimum triplicate) and biological replicates

  • Account for potential matrix effects through spike-recovery experiments

• Immunohistochemistry quantification:

  • Implement digital pathology approaches for objective quantification

  • Use automated image analysis software with appropriate algorithms for membrane protein detection

  • Develop standardized scoring systems that account for both staining intensity and distribution

  • Include reference standards in each staining batch for normalization across experiments

• qPCR correlation with protein data:

  • Compare PDZD3 protein levels measured by antibody-based methods with mRNA expression

  • Analyze discrepancies to identify potential post-transcriptional regulation

  • Calculate protein/mRNA ratios to assess translational efficiency

• Statistical analysis considerations:

  • Apply appropriate statistical tests based on data distribution (parametric vs. non-parametric)

  • Account for multiple comparisons when analyzing PDZD3 expression across various experimental conditions

  • Consider using ANCOVA when analyzing PDZD3 expression in relation to covariates

  • Implement power analysis to determine appropriate sample sizes for detecting biologically meaningful differences